Pharmacokinetic and pharmacodynamic study of lenograstim for hematopoietic stem cell mobilization: a prospective randomized study for optimal apheresis
暂无分享,去创建一个
C. Suh | D. Yoon | Ji Sung Lee | Jihoon Kang | Kyu-pyo Kim | J. Hong | J. E. Kim | S. Kim | Kyoungmin Lee | J. Park
[1] Peripheral , 2020, Definitions.
[2] M. Qazilbash,et al. Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy? , 2017, World journal of transplantation.
[3] A. Krishnan,et al. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation , 2015, Bone Marrow Transplantation.
[4] J. Dipersio,et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[5] H. Prince,et al. Peripheral blood CD34+ cell enumeration as a predictor of apheresis yield: an analysis of more than 1,000 collections. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[6] T. Geiger,et al. Prediction of CD34(+) cell yield in hematopoietic cell products from children by peripheral blood CD34(+) cell counts. , 2012, Cytotherapy.
[7] C. Moore,et al. Recommendations for Planning Pilot Studies in Clinical and Translational Research , 2011, Clinical and translational science.
[8] J. Kim,et al. Optimal timing of G-CSF administration for effective autologous stem cell collection , 2011, Bone Marrow Transplantation.
[9] B. Barlogie,et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) , 2009, Leukemia.
[10] A. Nademanee,et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. , 2009, Blood.
[11] U. Ergene,et al. Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT). , 2006, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[12] D. Dingli,et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. , 2006, Clinical lymphoma & myeloma.
[13] Steven A. Julious,et al. Sample size of 12 per group rule of thumb for a pilot study , 2005 .
[14] J. Huh,et al. Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin’s lymphoma , 2005, Annals of Hematology.
[15] N. Kröger,et al. Kinetics of G–CSF and CD34+ cell mobilization after once or twice daily stimulation with rHu granulocyte‐stimulating factor (lenograstim) in healthy volunteers: an intraindividual crossover study , 2004, Transfusion.
[16] S. Fruehauf,et al. It's moving day: factors affecting peripheral blood stem mobilization and strategies for improvement , 2003 .
[17] P. Feugier,et al. Hematologic recovery after autologous PBPC transplantation: importance of the number of postthaw CD34+ cells , 2003, Transfusion.
[18] S. Fruehauf,et al. It's moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement [corrected]. , 2003, British journal of haematology.
[19] J. Kigawa,et al. Timing of G-CSF Administration Based on the Circadian Rhythm in Patients With Ovarian Cancer , 2002, American journal of clinical oncology.
[20] D. Follmann,et al. Kinetics of G–CSF‐induced granulocyte mobilization in healthy subjects: effects of route of administration and addition of dexamethasone , 2002, Transfusion.
[21] W. Leisenring,et al. The predictive value of white cell or CD34+ cell count in the peripheral blood for timing apheresis and maximizing yield , 1999, Transfusion.
[22] Goldschmidt,et al. The dose of granulocyte colony‐stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ haemopoietic progenitor cells during marrow recovery , 1998, British journal of haematology.
[23] J. Miguel,et al. Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation , 1998, Transfusion.
[24] D. Linch,et al. Optimal timing for collection of PBPC after glycosylated G-CSF administration , 1998, Bone Marrow Transplantation.
[25] A. Zelenetz,et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] M. Kauppila,et al. Daily measurements of blood CD34+ cells after stem cell mobilization predict stem cell yield and posttransplant hematopoietic recovery. , 1997, Journal of hematotherapy.
[27] R. Hargreaves,et al. When to harvest peripheral-blood stem cells after mobilization therapy: prediction of CD34-positive cell yield by preceding day CD34-positive concentration in peripheral blood. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] A. Roberts,et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. , 1995, Blood.
[29] B. Barlogie,et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. , 1995, Blood.